Research programme: bispecific antibody therapeutics - Merus

Drug Profile

Research programme: bispecific antibody therapeutics - Merus

Alternative Names: MCLA-114; MCLA-122; MCLA-134; MCLA-158

Latest Information Update: 16 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merus
  • Developer Merus; ProBioGen
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD3 antigen modulators; Epidermal growth factor modulators; ERBB-3 receptor modulators; G protein-coupled receptor modulators; Programmed cell death-1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Colorectal cancer; Solid tumours
  • Research Multiple myeloma

Most Recent Events

  • 13 Mar 2018 Merus has patents pending for Spleen to Screen® technology in USA and other undisclosed countries
  • 06 Mar 2018 Merus has patent protection for Spleen to Screen® technology in USA, Europe, Asia, Australia
  • 08 Jan 2018 Bispecific antibodies licensed to Simcere Pharmaceutical Group in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top